Interventional Glaucoma

In a presentation at the Association for Research in Vision and Ophthalmology 2024 annual meeting in Seattle, researchers detailed a novel shunt, which could potentially improve postoperative IOP control and lower the risk of vision-threatening issues.

Priorities can ensure optimal outcomes for patients diagnosed with diseases.

Deborah Ristvedt, DO, in her Controversies in Modern Eye Care presentation, discussed the evolution from traditional glaucoma treatments to novel therapies that target the trabecular meshwork and that aim to optimize IOP management without the need for multiple medications.

Inder Paul Singh, MD, highlights how early intervention, modern techniques, and reduced medication burden can improve outcomes and quality of life for patients with glaucoma in his presentation at the Controversies in Modern Eye Care conference.

The 18th annual Controversies in Modern Eye Care conference, held on May 4, 2024, in Los Angeles, was co-chaired by Neda Shamie, MD, and Arjan Hura, MD, with the aim of discussing the latest advancements in eye care.

Rick Lewis, chief medical officer of ViaLase, describes the company's nonincisional glaucoma treatment, showing promising safety and efficacy in studies and possibly paving the way for FDA approval.

Alcon was ordered to pay $34 million to Sight Sciences after a trial by jury.

Deborah Gess Ristvedt, DO, shares highlights from her presentation and what these real-world cases mean for clinicians and their patients with glaucoma.

UPFs include fast food, energy drinks and soda, sweets such as chocolates and candies and much more.

The switch may produce an additional 25% IOP reduction in mild to moderate forms of disease

The technology uses a superelastic, memory-shaped nitinol guide that facilitates up to 360-degree guided circumferential removal of the trabecular meshwork.

The investigators conducted a multicenter, prospective, open-label, phase 4 study in which they evaluated the patients’ and investigators’ impressions of the drug.

The Osprey trial has started dosing while the Apteryx trial is anticipated to begin within the next few weeks.

One year after implantation, the enduring IOP reduction remained consistent across all 3 dose strengths.

The audiobook of GRF's flagship 40-page educational booklet "Understanding and Living with Glaucoma is narrated by Bianca Beach, an actress, advocate, and glaucoma patient.

Results from the trial by Nannodropper show microdrops could reduce waste, cost, and side effects while being as effective as traditional size drops.

According to the company, NCX 470 is a novel NO-donating bimatoprost eye drop, is currently in Phase 3 clinical development for the lowering of IOP in patients with open-angle glaucoma or ocular hypertension.

According to the foundation, the grants were awarded to 18 investigators at prominent universities in the United States, Nigeria, and Hong Kong.

LL-BMT1 is a novel, preservative-free, weekly drug-eluting contact lens created by the company’s proprietary 3D printing technology.

Study concluded that the short-term results of LBN to treat mild-to-modern OAG and OHT was safe and efficacious.

During the 2024 American Glaucoma Society meeting held February 29 to March 3 in Huntington Beach, California, Nixoc SA presented posters outlining data on NCX 470.

Repetitive exercises before drop instillation, may decrease difficulty and improve the successful instillation of eye drops.

The supplement is specifically crafted to promote healthy intraocular pressure (IOP), nurturing the well-being of retinal ganglion cells, and sustain the health of the retinal nerve fiber layer while boosting memory and concentration.

ECP105 has been developed for the recovery of post-surgical treatment of glaucoma.